IPO price: $13.50
Oct. 23 close: $15.02
Percentage gain: 11%
Tesaro ($TSRO) set a torrid pace to the public markets. Founded in 2010, the company notched a successful IPO this summer after in-licensing a pipeline of drugs for cancer patients and advancing its lead compound into late-stage development. And next year the Waltham, MA-based drug developer expects to report its first round of Phase III results.
To fuel its rapid rise, Tesaro has tapped its talented team of industry veterans, deep-pocketed venture backers and the active market for licensable pharma assets. The executive crew led by CEO Lonnie Moulder--who sold his previous company MGI Pharma for $3.9 billion--the company went out and raised well over $100 million from venture firms such as NEA, KPCB and Venrock and expertly plucked juicy clinical and preclinical stage assets from the pipelines of pharma giants such as Merck ($MRK) and Amgen ($AMGN) in a series of in-licensing deals.
The main attraction in the pipeline right now is rolapitant, a NK-1 receptor agonist, which is in Phase III development for preventing nausea and vomiting in cancer patients on chemotherapy. (Schering-Plough previously developed the compound, which was licensed out after Schering's megamerger with Merck in 2009.) Tesaro now expects to report top-line data from its Phase III program in the second half of 2013.
Further down the pipeline, Tesaro has a PARP inhibitor from Merck called niraparib in Phase I testing against solid tumors and a next-generation ALK inhibitor from Amgen with the expected lead indication of treating non-small cell lung cancer.
Tesaro raises $81M in a rare IPO success story
Tesaro nabs a Merck cancer drug for its pipeline
Tesaro promises rapid progress with cancer drugs in $86M IPO